In neonates with gastroesophageal reflux disease (GERD), both lansoprazole plus metoclopramide and  ranitidine plus metoclopramide displayed vital responses after one week and one month of therapy. However, the response rate was considerably better in the lansoprazole plus metoclopramide therapy compared with the ranitidine plus metoclopramide therapy.

A double-blind, randomized clinical trial was performed to explore efficacy and safety of lansoprazole plus metoclopramide vs. ranitidine plus metoclopramide to diminish GERD symptoms on the basis of  Infant Gastroesophageal Questionnaire Revised version (I-GERQ-R) scores in 120 neonates with GERD resistant to monotherapy and conservative therapy.

The enrolled neonates were randomly allocated to either oral lansoprazole plus metoclopramide arm or  oral ranitidine plus metoclopramide arm. After one week and one month, the alterations of signs symptoms and signs were recorded. In the end, 54 participants in each arm completed the trial and their data were assessed. 

The major endpoint was an alteration in the total number of GERD-linked signs and symptoms from baseline to the therapy end. The secondary endpoints were complications in either group after administration of lansoprazole, metoclopramide, and ranitidine.

After one week and one month, the response rate of  subjects treated with lansoprazole plus metoclopramide was considerably greater in comparison with the subjects treated with ranitidine plus metoclopramide. During the intervention, no treatment-emergent side effects were found in either arm. The combination of  acid suppressants with metoclopramide caused a greater response rate when compared to monotherapy utilized prior to the intervention. 

In GERD patients, the response rate is considerably elevated in  lansoprazole plus metoclopramide-treated patients compared with the ranitidine plus metoclopramide-treated patients.